Image
Improving Outcomes for Women With Type 2 Diabetes Individualizing Evidence-Based Care

Eileen Egan, DNP, FNP-C, CDE

This activity is jointly provided by Global Education Group and Integritas Communications.

This activity is supported by an educational grant from AstraZeneca Pharmaceuticals.

This program was planned in accordance with AANP CE Standards and Policies and AANP Commercial Support Standard.

Faculty

Eileen Egan, DNP, FNP-C, CDE
Chief Nurse Practitioner
Certified Diabetes Educator
Winthrop Center for Comprehensive Diabetes Care,
Winthrop Endocrine, Diabetes, & Metabolism Faculty Practice,
Mineola, New York
Adjunct Faculty
Department of Graduate Studies & Advanced Practice Nursing
Stony Brook University
Stony Brook, New York

Educational Objectives

Upon completion of this activity, participants will be better prepared to:

Discuss how disease manifestations and outcomes differ between women and men with T2DM

Assess female patients for T2DM based on risk factors and appropriate laboratory testing

Construct evidence-based treatment regimens for women with T2DM to reflect the degree of hyperglycemia, cardiovascular risk, comorbidities, and patient preferences

Target Audience

This educational activity is targeted to an audience of diabetes educators, endocrinologists, and other providers involved in managing type 2 diabetes mellitus (T2DM).

Statement of Need/Program Overview

Diabetes disorders afflict nearly 29 million adult Americans, 49% of whom are women.1-3 A growing body of evidence has uncovered important clinical differences between men and women with T2DM, suggesting greater burden of disease for female patients. For example, over the last decade, the risk of cardiovascular disease has declined among male patients with T2DM, whereas little change has been observed among female patients.4 Women with diabetes have a 44% greater risk of incident coronary heart disease compared with men with diabetes.5 Compared with their male counterparts, women with diabetes are also at greater risk for stroke,6 and generally present with lower energy and higher levels of depression or anxiety.7 Because much of the research on gender differences in T2DM is newly published, diabetes educators, endocrinologists, and other healthcare providers will benefit from case-based education on the practical implications of the emerging evidence, with the goal of improving outcomes among women with T2DM. This Interactive Professor™ program will examine sex differences in T2DM, recommendations on assessing women with T2DM, and evidence-based treatment regimens for female patients.

References

  1. Dabelea D, Bell RA, D’Agostino, Jr RB, et al. Incidence of diabetes in youth in the United States. JAMA. 2007; 297(24):2716-2724.
  2. Centers for Disease Control and Prevention. Diabetes Report Card, 2012. http://www.cdc.gov/diabetes/pubs/pdf/diabetesreportcard.pdf. Accessed July 2, 2015.
  3. Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014. http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf. Accessed July 2, 2015.
  4. Arnetz L, Ekberg NR, Alvarsson M. Sex differences in type 2 diabetes: focus on disease course and outcomes. Diabetes Metab Syndr Obes. 2014;7:409-420.
  5. Peters SA, Huxley RR, Woodward M. Diabetes as risk factor for incident coronary heart disease in women compared with men: a systematic review and meta-analysis of 64 cohorts including 858,507 individuals and 28,203 coronary events. Diabetologia 2014;57(8):1542-1551. 
  6. Peters SA, Huxley RR, Woodward M. Diabetes as a risk factor for stroke in women compared with men: a systematic review and meta-analysis of 64 cohorts, including 775,385 individuals and 12,539 strokes. Lancet. 2014;383(9933):1973-1980.
  7. Siddiqui MA, Khan MF, Carline TE. Gender differences in living with diabetes mellitus. Mater Sociomed. 2013;25(2):140-142.

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Global Education Group designates this activity for a maximum of 0.5 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Accreditation Statement

Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Global Education Group designates this continuing education activity for 0.5 contact hour(s) (0.05 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0530-9999-15-051-H01-P) This is a knowledge based activity.

Nurse Practitioner Continuing Education

Global Education Group is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners: AANP Provider Number 1101021. This program has been approved for 0.5 contact hours of continuing education (which includes 0.5 hours of pharmacology).

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or inquire@globaleducationgroup.com.

Instructions to Receive Credit

In order to receive credit, participants must complete the preactivity questionnaire, postactivity questionnaire, and program evaluation. Participants must also score at least a 70% on the posttest.

System Requirements

PC/MAC: Supports any web browser.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Eileen Eagan, DNP, FNP-C, CDE     Nothing to disclose.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Amanda Glazar, PhD     Nothing to disclose
Andrea Funk      Nothing to disclose
Kristen Delisi      Nothing to disclose
Jim Kappler, PhD     Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications.  

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Click "Begin Activity" to acknowledge that you have reviewed the preamble information for this activity.

Begin Activity

expiration 10/27/2016

type Webcast